echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Multicellular factor inhibitor BNZ-1 treats skin T-cell lymphoma: safe and effective.

    Multicellular factor inhibitor BNZ-1 treats skin T-cell lymphoma: safe and effective.

    • Last Update: 2020-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Biopharmaceuticals today announced that phase clinical trials have shown good safety and efficacy in treating patients with refracted skin cell lymphoma () for, and polycytokine inhibitorsThis phase of clinical research is designed to assess the safety and efficacy of single drug therapy in patients with standard care and treatment failuresThe study recruited a total of patientsThe primary endpoint is the overall safety after treatmentAfter the trial, the researchers extended the treatment for a period of several months to further assess safety and clinical responseOverall, there is good tolerance without dose-limiting toxicity
    The clinical symptoms of patients in the dose group improved significantlyThe results were as follows: more than % of the subjects improved the tumor burden without any accompanying therapy; about half of the patients received partial remission in the score (at least lower than the baseline), % of the subjects received full remission, and the average duration of remission was days (months) for those who achieved partial or complete remission at the time of the data cut-off in this mid-term analysis
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.